Hepatocellular carcinoma (HCC) is the most common type of primary malignancy in the liver. Main risk factors of HCC are well-defined and include hepatitis B virus (HBV); lifestyle, diet and environmental factors (e.g., alcoholic beverages, aflatoxin B1 (AFB1), and tobacco smoking); and metabolic diseases (e.g., obesity, diabetes and non-alcoholic steatohepatitis). Importantly, the rise in incidence of HCC in the developed countries has been attributed, at least in part, to an increase in hepatitis C virus (HCV) infections and non-alcoholic steatohepatitis, pathological states whose prevalence is growing in the US and Europe. In addition, liver fibrosis and cirrhosis are well known precursor liver disease states for hepatocellular HCC in humans. While animal model studies of HCC have contributed much of the understanding of the molecular events leading to disease initiation, progression and promotion, few publications examined co-morbidity factors that are known to contribute to HCC in humans. This presentation will describe two examples of experimental animal models of HCC where co-morbidity factors (HCV+AFB1, or genotoxic carcinogen diethylnitrosamine+liver fibrosis) were explored. These studies afford an opportunity to examine the molecular mechanisms that are crucial for the synergy between co-morbidity factors.


Article metrics loading...

Loading full text...

Full text loading...

  • Received: 08 May 2012
  • Accepted: 08 May 2012
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error